**Q** 

0

- Review of regulatory guidelines and policies to provide consolidated cross industry responses
- Identification of regulatory statistical issues that are of concern across industry for discussion with regulators
- Engagement with MHRA statisticians and EMA Methodology Working Party

Promotion of best practice and driving debate on future guidelines

- 21 members from 8 countries and 20 companies,
- Led by Jürgen Hummel (Novo Nordisk, UK) for PSI and Christoph Gerlinger (Bayer, Germany) for EFSPI

BIONTECH

parexel



AstraZeneca 2





Cytel

















**D** 

7

0











## Medicines & Healthcare products Regulatory Agency

ROPEAN MEDICINES AGENCY

Purpose

To co-ordinate regulatory activities across the **European Pharmaceutical** Statistical community and to engage with Regulatory statisticians

- Scan regulatory guidelines for statistical content and comment
- Annual meeting with MHRA statisticians (jointly with EFSPI Methods Leaders ESIG)
- From 2013 to 2021, annual meeting with EMA Biostatistics Working Party
- Help to organize the EFSPI workshop on Regulatory Statistics and the PSI training course: Regulatory Guidelines for Statisticians
- Co-organize Regulatory Hot Topics session at PSI Conference
- Connect with other ESIGs

- The Regulatory ESIG is probably the longest serving ESIG, dating back to at least 2006
- The ESIG had a role in founding the EFSPI Regulatory Workshop
- It was originally formed as a PSI Regulatory Committee and transitioned to a joint PSI/EFSPI Committee around 2013
- At the end of 2020 it renamed from a Committee to an ESIG





